Sarepta Therapeutics (NASDAQ:SRPT) Research Coverage Started at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report issued on Tuesday, MarketBeat.com reports. The brokerage issued a hold rating and a $136.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on SRPT. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Guggenheim upped their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $109.46 on Tuesday. The firm has a market cap of $10.46 billion, a PE ratio of 87.57 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a 50 day moving average of $119.82 and a 200 day moving average of $125.11. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Manchester Capital Management LLC grew its position in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. grew its position in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank grew its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.